Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Madrigal Pharmaceuticals, Inc. MDGL
$287.43
-$0.69 (-0.24%)
На 18:00, 12 мая 2023
-7.24%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
5225136291.00000000
-
week52high
322.67
-
week52low
57.21
-
Revenue
0
-
P/E TTM
-18
-
Beta
-0.62145300
-
EPS
-16.88000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:30
Описание компании
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Neutral | Buy | 08 июл 2022 г. |
| Oppenheimer | Outperform | Outperform | 10 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 10 мая 2022 г. |
| Jefferies | Buy | 07 окт 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 11 авг 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 05 янв 2023 г. |
| UBS | Buy | Buy | 21 дек 2022 г. |
| Oppenheimer | Outperform | Outperform | 20 дек 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Levy Richard S | D | 0 | 10000 | 17 янв 2023 г. |
| Levy Richard S | D | 0 | 10000 | 17 янв 2023 г. |
| Levy Richard S | D | 9100 | 500 | 17 янв 2023 г. |
| Levy Richard S | D | 9600 | 2325 | 17 янв 2023 г. |
| Levy Richard S | D | 11925 | 5164 | 17 янв 2023 г. |
| Levy Richard S | D | 17089 | 3548 | 17 янв 2023 г. |
| Levy Richard S | D | 20637 | 5227 | 17 янв 2023 г. |
| Levy Richard S | D | 25864 | 3325 | 17 янв 2023 г. |
| Levy Richard S | D | 29189 | 1600 | 17 янв 2023 г. |
| Levy Richard S | D | 30789 | 300 | 17 янв 2023 г. |
Новостная лента
Why Madrigal Pharmaceuticals Stock Is Slumping Today
The Motley Fool
09 мая 2023 г. в 13:54
Madrigal Pharmaceuticals stock plummeted in early-morning trading following its 2023 Q1 earnings report. Bargain hunters were quick to buy the dip, however.
3 Biotechs That Might Get Bought Out in 2023
The Motley Fool
26 апр 2023 г. в 11:30
With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors soon.
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
The Motley Fool
20 апр 2023 г. в 14:06
On Tuesday, Madrigal won an important regulatory designation from the FDA for its NASH candidate. The biotech got another boost from the ongoing buyout bonanza in biotech.
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Benzinga
20 апр 2023 г. в 08:07
Where is the current bull market? All indications would be that it's in biotech!
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
Zacks Investment Research
19 апр 2023 г. в 15:12
Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.